Analytica Annual Update 2016; Successfully Raised $0.5m During Their SPP, Obtained US FDA Clearance & Chinese Patent Protection

Analytica’s lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. In 2016, Analytica successfully raised $0.5m during their SPP. Following on from this outstanding achievement, below is listed many more of the company’s triumphs:

• Shares were issued at 0.255 cents per share
• A further placement of $280,000, at the same price as the SPP, was allocated to non-related parties.
• A further placement of $500,000 to INOV8 LLC at the same price as the SPP was issued.
• At placement of $1 million to myself (M Monsour) at the price of 0.3cents was also announced subject to shareholder approval.
• Approval for these placements was granted at the EGM in April this year.
• July 2016 – obtained US FDA Clearance- PeriCoach Over-The-Counter.
• August 2016 – Patent protection for the PeriCoach was granted for China.
• Our Engineering department has prioritised development of PeriCoach Version 3.
• AutoStart Burette listed on the Queensland Health purchasing schedule July 2016. Hospitals trialling this technology.
• AutoStart Burette granted US Patent protection July 2016.
• Medical Technology Association of Australia outstanding achievement award presented Ms Cornelius.

Analytica is currently capital raising for $1.442 million, funds raised under the Placement will be used for working capital and to roll out PeriCoach Version 3.